BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $21.73 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 61.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,674 shares of the biopharmaceutical company’s stock after purchasing an additional 7,840 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Regeneron Pharmaceuticals were worth $21,729,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. SteelPeak Wealth LLC increased its position in Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares during the period. Atria Investments Inc raised its position in shares of Regeneron Pharmaceuticals by 12.2% during the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after acquiring an additional 941 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Regeneron Pharmaceuticals by 23.2% in the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after purchasing an additional 5,495 shares during the last quarter. Tri Locum Partners LP boosted its holdings in Regeneron Pharmaceuticals by 104.5% during the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after buying an additional 8,949 shares during the last quarter. Finally, Tidal Investments LLC grew its position in shares of Regeneron Pharmaceuticals by 16.8% during the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after buying an additional 711 shares during the period. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares in the company, valued at $13,540,179.41. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. Over the last three months, insiders have sold 9,270 shares of company stock worth $10,695,833. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $1,045.98 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The business has a 50-day moving average of $1,130.96 and a 200-day moving average of $1,034.01. The stock has a market capitalization of $115.31 billion, a price-to-earnings ratio of 30.90, a PEG ratio of 3.72 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.79 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on REGN. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Truist Financial reissued a “buy” rating and issued a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday. Wells Fargo & Company reaffirmed an “overweight” rating and set a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Guggenheim increased their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,118.62.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.